Skip Navigation LinksHome > May 2010 - Volume 32 - Issue 4 > The Effect of Dexrazoxane for Clinical and Subclinical Cardi...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3181d321b3
Original Articles

The Effect of Dexrazoxane for Clinical and Subclinical Cardiotoxicity in Children With Acute Myeloid Leukemia

Sánchez-Medina, Jerónimo MD*; Gonzalez-Ramella, Oscar PhD; Gallegos-Castorena, Sergio MD

Collapse Box


Cardiotoxicity is frequently present with anthracycline treatment. Most acute myeloid leukemia (AML) protocols use anthracyclines. Dexrazoxane has cardioprotective activity. The aim of this study was to evaluate cardioprotection of dexrazoxane in a prospective study. Fifty pediatric AML patients were treated with a Medical Research Council AML 10 modified protocol with dexrazoxane previous to any anthracycline dose. Cardiac function was evaluated at diagnosis, before every cycle, and every 6 months after the end of chemotherapy. Accumulative doses of anthracycline reached 424 mg/m2 (150 to 850 mg/m2). Forty-eight patients (96%) received a dose higher than 300 mg/m2. Twenty-eight percent had a grade of cardiotoxicity (24% grade 1 and 4% grade 2). Non 3 or 4 grade cardiotoxicity was seen. Cumulated anthracycline doses did not correlated with cardiotoxicity (P=0.815). The event-free survival was 53%, 15.7% died of disease, and 11.8% died free of leukemia. There is still not an agreement for the optimal method to reduce cardiotoxicity in children receiving anthracyclines. In our study, we could conclude that the use of dexrazoxane was effective cardioprotectant to allow a high-dose of anthracycline therapy. A randomized study is necessary to consolidate this asseveration.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us


For additional oncology content, visit LWW Oncology Journals on Facebook.